L
Laboratoires Cyclopharma SA
Laboratoires Cyclopharma SA developing innovative molecular imaging solutions
About Laboratoires Cyclopharma SA
Laboratoires Cyclopharma SA, founded in 2000, is a French pharmaceutical company specializing in molecular imaging solutions. The company develops, produces, and distributes radiopharmaceutical tracers for diagnostic imaging in oncology, neurology, and cardiology to healthcare professionals. These tracers are used with Positron Emission Tomography (PET) and Single-Photon Emission Computed Tomography (SPECT) scans to visualize tumors and other pathologies, aiming to improve therapeutic efficacy and patient outcomes.
In December 2013, the DENOS Group, led by Olivier Carli, acquired a majority stake in Cyclopharma in a transaction exceeding €10 million. This strategic move was intended to finance the market entry of new radiopharmaceutical products and accelerate the company's international expansion. Following the acquisition, Carli, a serial entrepreneur in the MedTech and BioTech sectors, became president, leading an experienced management team from the pharmaceutical industry. Before the acquisition, Cyclopharma had raised funds from investors including Bpifrance, CDC Enterprises, Crédit Agricole, and Societe Generale Capital Partenaires.
A significant milestone occurred in April 2018 when Curium acquired Cyclopharma's French production facilities and commercial operations. This transaction integrated Cyclopharma's seven PET radiopharmacies in France into Curium's network, enhancing production capabilities and coverage across the country. The research and development programs, along with international development projects and the US division, were not part of the deal and were spun off into a new company named Zionexa, owned by the historical shareholder, DENOS Group. This new entity focuses on developing and commercializing innovative diagnostic and therapeutic solutions, such as EstroTep, a PET tracer for breast cancer diagnosis.
Source: Dealroom company dataAt a glance
- Outcome tier
- Colt$25–100M revenue
News
Open roles
Laboratoires Cyclopharma SA in the Saint-Beauzire ecosystem
The Laboratoires Cyclopharma SA office with the hot startups, most funded companies and investors around it. Hover or tap a pin.
Dealroom maps whole ecosystems like this one for cities, regions and governments. See the ecosystem platform →
Investors
From Dealroom's funding and investor records, grouped by the round each investor first entered.
Series B and later1 investor entered at this stage
iXO Private Equity
Source: Dealroom Talent Intelligence.
Global footprint
team presence
Market sentiment
An AI-synthesised read of the highest-engagement posts about Laboratoires Cyclopharma SA on X, ranked by likes and reposts, corporate channels excluded.
Reading the room on X — pulling top posts and synthesizing themes…
Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour
See Laboratoires Cyclopharma SA on the full Dealroom platform
Live deal flow, founder pedigree, hiring signals, revenue trajectory, and the full cap table.


